A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.

Abstract:

BACKGROUND:Ursodeoxycholic acid (UDCA) prolongs transplantation-free survival in primary biliary cirrhosis (PBC). However, the optimal therapeutic dose has not been established. AIM:To compare the effects of UDCA administered in daily doses of 10 vs. 20 mg/kg on symptoms, liver biochemistry and biliary UDCA enrichment. METHODS:A 6-month multicentre randomized open controlled trial was conducted to assess the effects of an increase in the dose of UDCA to 20 mg/kg/day vs. continuation of 10 mg/kg/day for patients who had not achieved biochemical normalization during treatment for at least 6 months with the 10 mg/kg dose. Clinical and laboratory evaluations were performed at entry and at 3-month intervals. The percentage UDCA in duodenal bile was assessed at entry and at 6 months. RESULTS:Sixty-one patients were enrolled. No side-effects of UDCA were observed. Within the 20 mg/kg/day group significant decreases were found for alkaline phosphatase (- 8%; P = 0.003), aspartate aminotransferase (- 11%; P = 0.01), alanine aminotransferase (- 17%; P < 0.001), gamma-glutamyl transferase (- 34%; P < 0.001), immunoglobulin M (- 11%; P = 0.002) and cholesterol (- 8.1%; P < 0.001). In the 10 mg/kg group none of these parameters differed significantly from baseline. No significant differences between dose groups for symptom scores or serum bilirubin were found. Biliary enrichment with UDCA increased from 37% to 46% in the 20 mg/kg group (P = 0.02) while remaining stable in the 10 mg/kg group. CONCLUSIONS:Liver biochemistry improved in PBC patients receiving UDCA 20 mg/kg/day compared to a dose of 10 mg/kg/day. Both doses were equally well tolerated. These results indicate that UDCA 10 mg/kg/ day is a suboptimal dose for treating PBC.

journal_name

Aliment Pharmacol Ther

authors

Van Hoogstraten HJ,De Smet MB,Renooij W,Breed JG,Engels LG,Den Ouden-Muller JW,Rijk MC,Smit AM,Zwertbroek R,Hop WC,van Berge Henegouwen GP,Schalm SW,van Buuren HR

doi

10.1046/j.1365-2036.1998.00395.x

subject

Has Abstract

pub_date

1998-10-01 00:00:00

pages

965-71

issue

10

eissn

0269-2813

issn

1365-2036

journal_volume

12

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Review article: the medical management of Crohn's disease.

    abstract::The choice of medical therapies for Crohn's disease continues to grow. Although our understanding of the mechanisms of the disease is incomplete, increasing knowledge of the pathogenesis of inflammation in general and Crohn's disease in particular allows targeting of therapies at various points in the immunoinflammato...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1996.tb00173.x

    authors: Elton E,Hanauer SB

    更新日期:1996-02-01 00:00:00

  • A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn.

    abstract:BACKGROUND:Ranitidine 75 mg (Zantac 75) has been shown to be effective for the treatment of pre-existing heartburn symptoms. AIM:To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms. METHODS:A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1999.00505.x

    authors: Pappa KA,Williams BO,Payne JE,Buaron KS,Mussari KL,Ciociola AA

    更新日期:1999-04-01 00:00:00

  • Rat CXC chemokine GRO/CINC-1 paradoxically stimulates the growth of gastric epithelial cells.

    abstract:BACKGROUND:CXC chemokines such as interleukin (IL)-8 are neutrophil chemoattractants, the levels of which increase in Helicobacter pylori-infected gastric mucosa. Many investigators have focused on the chemotactic aspects of IL-8: however, CXC chemokines are also reported to have angiogenic activity and to serve as rem...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.014s1094.x

    authors: Suzuki H,Mori M,Seto K,Shibata F,Nagahashi S,Kawaguchi C,Suzuki M,Matsui H,Watanabe K,Miura S,Ishii H

    更新日期:2000-04-01 00:00:00

  • Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease.

    abstract:BACKGROUND:Refractory sprue with malabsorption carries a risk of lymphoma. AIM:To examine whether a good clinical but poor histological response during a strict gluten-free diet predicts a poor outcome. METHODS:The study involved all coeliac patients who showed no histological recovery within 2 years on a strict glut...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2007.03311.x

    authors: Kaukinen K,Peräaho M,Lindfors K,Partanen J,Woolley N,Pikkarainen P,Karvonen AL,Laasanen T,Sievänen H,Mäki M,Collin P

    更新日期:2007-05-15 00:00:00

  • Review article: maintenance treatment of Crohn's disease.

    abstract::The aetiology of Crohn's disease is unknown and therefore no curative treatments are available for the disease. The natural history of Crohn's disease is characterized by recurrent flare-ups of symptoms. Several drug treatments are effective in inducing clinical remission. However, no drug treatments are available in ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.17.s2.20.x

    authors: Biancone L,Tosti C,Fina D,Fantini M,De Nigris F,Geremia A,Pallone F

    更新日期:2003-06-01 00:00:00

  • Review article: impact of night-time reflux on lifestyle - unrecognized issues in reflux disease.

    abstract::Gastro-oesophageal reflux disease (GERD), manifesting with symptoms including heartburn and regurgitation, affects people during both daytime and nocturnal hours. Night-time GERD has been reported to have a greater impact on a patient's life than daytime GERD due to prolonged oesophageal acid exposure time per reflux ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02237.x

    authors: Shaker R,Brunton S,Elfant A,Golopol L,Ruoff G,Stanghellini V

    更新日期:2004-12-01 00:00:00

  • Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort.

    abstract:BACKGROUND:Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC). AIMS:To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04711.x

    authors: Vienne A,Simon T,Cosnes J,Baudry C,Bouhnik Y,Soulé JC,Chaussade S,Marteau P,Jian R,Delchier JC,Coffin B,Admane H,Carrat F,Drouet E,Beaugerie L

    更新日期:2011-07-01 00:00:00

  • Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.

    abstract:BACKGROUND:Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS:To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FD...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15726

    authors: Dulai PS,Jairath V,Khanna R,Ma C,McCarrier KP,Martin ML,Parker CE,Morris J,Feagan BG,Sandborn WJ

    更新日期:2020-06-01 00:00:00

  • Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2004.02294.x

    authors: Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

    更新日期:2005-01-01 00:00:00

  • Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.

    abstract:BACKGROUND:Travellers' diarrhoea, a common problem worldwide with significant medical impact, is generally treated with anti-diarrhoeal agents and fluid replacement. Systemic antibiotics are also used in selected cases, but these may be associated with adverse effects, bacterial resistance and drug-drug interactions. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04296.x

    authors: Layer P,Andresen V

    更新日期:2010-06-01 00:00:00

  • Twenty-four-hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily.

    abstract::Twenty-four-hour intragastric acidity was measured in 10 patients with a past history of duodenal ulcer on the fourth day of dosing with placebo, and either 150 mg ranitidine given twice or four times daily. The order of the treatments was randomized and a double-blind design was employed. Ranitidine (150 mg) b.d. dec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00211.x

    authors: Howden CW,Tsai HH,Reid JL

    更新日期:1989-06-01 00:00:00

  • Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication.

    abstract:BACKGROUND:Many patients are not symptom-free after eradication therapy for Helicobacter pylori and continue to use proton pump inhibitors or H2-receptor antagonists (H2-RAs). AIM:To ascertain whether a cohort of patients treated for H. pylori were still taking either proton pump inhibitors or H2-RAs more than 4 years...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1999.00626.x

    authors: Tan AC,Hartog GD,Mulder CJ

    更新日期:1999-11-01 00:00:00

  • Acute liver failure in Scotland: changes in aetiology and outcomes over time (the Scottish Look-Back Study).

    abstract:BACKGROUND:Acute liver failure is a rare and devastating clinical condition resulting from sudden loss of hepatic parenchyma and metabolic function. The Scottish Liver Transplant Unit (SLTU) offers specialist management and emergency liver transplantation to patients with acute liver failure from across Scotland. AIM:...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13943

    authors: Donnelly MC,Davidson JS,Martin K,Baird A,Hayes PC,Simpson KJ

    更新日期:2017-03-01 00:00:00

  • High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

    abstract:BACKGROUND:Strong acid inhibition using esomeprazole increases cure rates with triple therapy and 10-day treatments are more effective than 7-day ones. The combination of amoxicillin plus metronidazole at full doses, and using a physiologically-correct schedule three times a day, and has been shown to overcome metronid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05137.x

    authors: Sánchez-Delgado J,García-Iglesias P,Castro-Fernández M,Bory F,Barenys M,Bujanda L,Lisozain J,Calvo MM,Torra S,Gisbert JP,Calvet X

    更新日期:2012-07-01 00:00:00

  • Clinical predictors of fibrosis in patients with chronic liver disease.

    abstract:BACKGROUND:Patients with chronic liver disease and components of metabolic syndrome may be at higher risk for fibrosis. AIM:To assess the impact of clinicodemographic factors on hepatic fibrosis in CLD. METHODS:Of 1028 chronic liver disease patients, 964 were included in the analysis. Extensive clinico-demographic an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04266.x

    authors: Stepanova M,Aquino R,Alsheddi A,Gupta R,Fang Y,Younossi Z

    更新日期:2010-05-01 00:00:00

  • Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages.

    abstract:BACKGROUND:Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD. Carriers have been reported to better respond to lifestyle modification. AIM:To investig...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13232

    authors: Mangge H,Baumgartner BG,Zelzer S,Prüller F,Schnedl WJ,Reininghaus EZ,Haybaeck J,Lackner C,Stauber R,Aigner E,Weghuber D

    更新日期:2015-07-01 00:00:00

  • Review article: albumin for circulatory support in patients with cirrhosis.

    abstract::Renal function abnormalities and ascites in cirrhosis are the final consequence of a circulatory dysfunction characterized by marked splanchnic arterial vasodilation. This causes a reduction in effective arterial blood volume and the homoeostatic activation of vasoconstrictor and sodium-retaining systems. Albumin is v...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.16.s5.4.x

    authors: Ginès P,Guevara M,De Las Heras D,Arroyo V

    更新日期:2002-12-01 00:00:00

  • Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole.

    abstract:BACKGROUND:The effects of proton pump inhibitors and Helicobacter pylori infection on the distribution of drugs used for the eradication of the bacteria are poorly understood. AIM:The aim of this study was to investigate the effects of a 7-day administration of 20 mg of omeprazole on the pharmacokinetics of amoxicilli...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01262.x

    authors: Ortiz RA,Calafatti SA,Corazzi A,Souza JM,Deguer M,De Souza CA,Marchioretto MA,Bernasconi G,Ferraz JG,Pedrazzoli J Jr

    更新日期:2002-06-01 00:00:00

  • Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.

    abstract:BACKGROUND:Low bone mineral density (BMD) has been reported in both paediatric and adult patients with non-alcoholic fatty liver disease (NAFLD). The mechanisms behind the reduced BMD in NAFLD are still not completely understood. AIM:To provide a critical overview of the pathophysiological pathways linking NAFLD, redu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05196.x

    authors: Yilmaz Y

    更新日期:2012-08-01 00:00:00

  • Review article: the long-term use of proton-pump inhibitors.

    abstract::More than 15 years after the launch of omeprazole in 1988, proton-pump inhibitors remain central to the management of acid-suppression disorders and are unchallenged with regard to their efficacy and popularity among doctors and patients. They are considered safe despite early concerns about the possibility of an asso...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2005.02611.x

    authors: Raghunath AS,O'Morain C,McLoughlin RC

    更新日期:2005-08-01 00:00:00

  • Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

    abstract:BACKGROUND:Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02690.x

    authors: Lupascu A,Gabrielli M,Lauritano EC,Scarpellini E,Santoliquido A,Cammarota G,Flore R,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期:2005-12-01 00:00:00

  • Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.

    abstract:BACKGROUND:Third-generation cephalosporins (TGC) constitute the empirical first-line therapy for spontaneous bacterial peritonitis (SBP). Hospitalisation, invasive procedures and use of antibiotics may challenge this concept due to an increase in enterococci and other TGC-resistant microorganisms. AIM:To determine pre...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05076.x

    authors: Reuken PA,Pletz MW,Baier M,Pfister W,Stallmach A,Bruns T

    更新日期:2012-05-01 00:00:00

  • Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease affects 10-35% of the adult population worldwide; there is no consensus on its treatment. Omega-3 fatty acids have proven benefits for hyperlipidaemia and cardiovascular disease, and have recently been suggested as a treatment for non-alcoholic fatty liver disease. AIMS:To ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04230.x

    authors: Masterton GS,Plevris JN,Hayes PC

    更新日期:2010-04-01 00:00:00

  • Review article: esomeprazole in the treatment of Helicobacter pylori.

    abstract::Proton pump inhibitor-based triple therapy is the most commonly used treatment for eradication of Helicobacter pylori, with pooled eradication rates of approximately 90%. In the USA, per protocol eradication rates with 10-day proton pump inhibitor-based triple therapy are approximately 85%. Esomeprazole, a new proton ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.16.s4.13.x

    authors: Laine L

    更新日期:2002-07-01 00:00:00

  • The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose.

    abstract:BACKGROUND:The sequential organ failure assessment (SOFA) score is an effective triage marker following single time point paracetamol (acetaminophen) overdose, but has not been evaluated following staggered (multiple supratherapeutic doses over >8 h, resulting in cumulative dose of >4 g/day) overdoses. AIM:To evaluate...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05102.x

    authors: Craig DG,Zafar S,Reid TW,Martin KG,Davidson JS,Hayes PC,Simpson KJ

    更新日期:2012-06-01 00:00:00

  • Comparative assessment of phenolphthalein and phenolphthalein glucuronide: is phenolphthalein glucuronide a better laxative?

    abstract:BACKGROUND:Phenolphthalein is widely used as a safe and effective laxative. After oral administration, phenolphthalein is absorbed in the small bowel and is conjugated in the liver to phenolphthalein glucuronide which passes into the colon where it is deconjugated and the active compound, phenolphthalein, is released. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00331.x

    authors: Anand BS,Torres E,Operkun A,Graham DY

    更新日期:1994-10-01 00:00:00

  • Clarithromycin-amoxycillin therapy for Helicobacter pylori infection.

    abstract:BACKGROUND:More convenient therapies are needed to treat Helicobacter pylori infection successfully. Clarithromycin and amoxycillin are effective against H. pylori both in vivo and in vitro. Recent success with a high dose amoxycillin-metronidazole combination therapy led us to evaluate clarithromycin-amoxycillin dual ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1994.tb00313.x

    authors: al-Assi MT,Genta RM,Karttunen TJ,Graham DY

    更新日期:1994-08-01 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract:BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13950

    authors: Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期:2017-04-01 00:00:00

  • Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

    abstract:BACKGROUND:Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link. AIM:To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and respons...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03185.x

    authors: Qua CS,Wong CH,Gopala K,Goh KL

    更新日期:2007-02-01 00:00:00

  • Pyloric gland metaplasia and pouchitis in patients with ileal pouch-anal anastomoses.

    abstract:BACKGROUND:Diagnosis and management of chronic antibiotic-refractory pouchitis and Crohn's disease of the pouch can be challenging. Pyloric gland metaplasia is a histological feature indicative of chronic mucosal inflammation. Its value in diagnosis and prognosis of pouch disorders has not been investigated. AIM:To as...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2010.04249.x

    authors: Kariv R,Plesec TP,Gaffney K,Lian L,Fazio VW,Remzi FH,Lopez R,Goldblum JR,Shen B

    更新日期:2010-04-01 00:00:00